enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD · Warrants
2.750
-0.160 (-5.50%)
At close: Jan 30, 2026, 4:00 PM EST
2.500
-0.250 (-9.09%)
After-hours: Jan 30, 2026, 4:00 PM EST
-5.50%
Market Cap638.36M +68.5%
Revenue (ttm)n/a
Net Income-117.30M
EPS-2.29
Shares Out 66.98M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume121,712
Open3.200
Previous Close2.910
Day's Range2.250 - 3.230
52-Week Range0.510 - 4.200
Beta-0.28
Analystsn/a
Price Targetn/a
Earnings DateMar 9, 2026

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 82
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile